Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cotinga Pharmaceuticals Inc COTQF

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.


GREY:COTQF - Post by User

Comment by DIYGuyon Jun 23, 2017 6:03pm
336 Views
Post# 26400138

RE:Share consolidations are amateurish at best

RE:Share consolidations are amateurish at best
Had all day to think about this share consolidation. It doesn't pass the smell test to me. As previously mentioned, who cares about the share price. It's irrelevant and should only be about market valuation when it comes to institutional investors. 
 
So, here is what I think happens. The reverse split goes through and we drift down to $1.50 range (~22MM mkt cap). Financing done for $3MM or 2 MM new shares issued, which would represent 13% ownership. None of this happens if the clinical trial is a bust and we drift even lower. Totally a guess on my part.
 
It all comes down to why were two, not one PR firms hired if the trial did not go well. Fooled me big time. I gambled and lost big (on paper so far). Why not save the cash for COTI-219? 
 
One very small positive is they did not change their name.
 
Have a great weekend and hope for some news next week, but I am very skeptical.
<< Previous
Bullboard Posts
Next >>